Abiopharma

News list

(99% Neutral) ObsEva SA (company was delisted NASDAQ) (OBSV) Announces Clinical Development Update (Form 6-K)

Full text

News bot Oct. 18, 2025, 6:11 p.m.
🌍 ObsEva SA (company was delisted NASDAQ) (OBSV) - Form 6-K Filing

Filing Date: 2022-08-01

Accepted: 2022-08-01 07:21:59

Event Type: Clinical Trial Update

Event Details:

1 ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing Ad hoc announcement pursuant to Art. Additionally, the Company has entered into an amendment and forbearance agreement with respect to the outstanding debt held by JGB. 5 million was added to the outstanding principal balance under the notes, resulting in an aggregate of approximately $11 million of convertible notes out.
💼 Business Developments:
- ✅ Partnership/Collaboration
- ❌ Acquisition Activity: Not reported
- ✅ Licensing Agreement
- ❌ Regulatory Milestone: Not reported
- ❌ Leadership Updates: Not reported
📞 Contact Information:
- Investor Contact: Katja Buhrer katja.buhrer@obseva.com +1 (917) 969-3438
- Email: shauna.dillon@obseva.ch